I wanted to discuss Tocilizumab. I know it has been brought up before, but seemed to be brushed to the side. Targeting IL-6, there are some serious side effects listed, there is no warning on the label and this pathway in theory should help with the cytokines storm. Also it is safe to say the occurrence of these side effects will be less, as patients will receive a limited number of injections.

They have started phase 3 (severe patients) a couple weeks ahead of us, and they can begin interim results analysis after the first 60 patients. They are ahead of us and have a lot more resources. Now efficacy could be less than Leronlimab, but first to strike will be huge. Also they are approved for other indications and supply wouldn’t be an issue.

Thoughts? Please don’t just list side effects and dismiss this drug. It is IMO our biggest competitor.

I am long CYDY but this covid play puts us in a fierce field of competition.